Background: Cryptococcal meningitis (CM) remains a significant cause of death amongst individuals with HIV-1 infection. Immune correlates of protection are lacking. Animal and in vitro studies suggest macrophage and monocyte activation plays a key role in determining outcome from infection. This study examines the relationship between peripheral blood monocyte activation and clinical outcome in patients with HIV-1-associated CM. Methodology: Patients with HIV-1-associated CM were recruited from hospitals in Cape Town. Initial anti-fungal therapy was IV amphotericin 1mg/kg and oral fluconazole 800mg per day. Monocyte sub-populations and their activation phenotype were characterized in whole blood at baseline using flow cytometry. Intracellular cytokine responses were assessed following 6-hour stimulation with lipopolysaccharide (LPS) and R848 (TLR7/8 agonist). Comparisons in baseline monocyte activation were made between subjects who survived to 14 days and those who died. Results: 59 subjects were enrolled, median CD4 count was 34×106/ml and 14-day mortality was 24%. Compared to survivors (S), non-survivors (NS) had significantly lower expression of HLA-DR, and significantly higher expression of CD163, on CD14+CD16+ monocytes at baseline (mean HLA-DR MFI 7272 (S) vs 4197 (NS); mean CD163 MFI 10541 (S) vs 17420 (NS); p=0.007 and p=0.03 respectively). In addition, following LPS stimulation monocyte cytokine responses were impaired in non-survivors, with significantly fewer monocytes producing TNFα (26% (NS) vs 44% (S), p=0.002). However, there was no difference in monocyte responses following TLR7/8 stimulation (see table). Conclusions: This study suggests impaired monocyte function may be an important factor determining poor outcome in cryptococcal disease. This may reflect overstimulation, and compensatory down-regulation, of inflammatory responses in circulating monocytes. Reversal of this defect may be a potential immune-based therapeutic strategy.